Related by context. All words. (Click for frequent words.) 87 iii 82 ii 76 vii 73 viii 73 vi 68 ix 65 xvi 65 xii 65 xv 65 xxii 64 xiii 64 xviii 63 xi 62 Immtech scientists 61 xvii 61 xix 61 Immtech clinical trials 61 xxvi 60 xxi 60 xiv 57 DSL.net s 57 #.#-# b [001] 56 Pure Biofuels ability 56 ourability 56 iii iv 55 #.#-# b [002] 55 xxv 55 xxiv 55 Textainer expectation 54 ecommerce marketplaces 54 xxviii 54 § #-#-# b [003] 54 related thereto 53 xxvii 53 changesin 53 withrespect 53 § #.#-# [007] 53 xxiii 53 b 52 vii viii 52 impactof 52 [013] 52 P. #a 52 xxxii 52 Legal #.# 52 § #.#-# [004] 52 d Reflects 51 collect reinsurance recoverables 51 j 51 risksassociated 51 Projects Initiation 51 without limitation 51 USC § #f 51 ii iii 51 orother 51 vi vii 50 thereof 50 thereunder 50 i #.# subds 50 HANA MAX 50 Income Tax Regs 50 lender consents 50 theCompany 50 communicate differentiations effectively 49 competitively procured pursuant 49 minerals inc 49 relating 49 NASD Marketplace Rule 49 § #-#-# b [001] 49 DTR #.#.# b 49 #.#-# [020] 49 aresubject 49 CFR #.# [002] 49 representations warranties covenants 49 Consists 49 SURETY LICENSES c 48 renegotiation nullification 48 theability 48 relatedto 48 successfully integrate 48 Cerro Negro concession 48 including withoutlimitation 48 CFR § #.# [006] 48 #.# subd [003] 48 regarding Heska 48 marketconditions 48 GrowthWorks refers 48 prepayment speeds loan originations 48 examinations vaccinations spaying 48 f [001] 48 Colo. Sess 48 TCA § #-#-# [003] 48 incur unanticipated 48 inventory obsolescence 48 toreflect 48 CFR #.#b 48 securityholder approvals 48 constitutes discloseable transaction 48 DIP Loan 48 Offerors Commercial applies 47 governmental approvals 47 relapsed acute myelogenous 47 party payors 47 Kyowa Kirin 47 applicable 47 CFR § #.# [008] 47 love veronica Mars 47 economicconditions 47 general economicconditions 47 #.#-# Equal Opportunity 47 PharMerica LTC Transaction 47 counterparty creditworthiness 47 PGP Acquisition 47 CFR § #.# [004] 47 CFR § #.# [007] 47 See USSG § #B#.# 47 results ofoperations 47 d Represents 47 associated therewith 47 § #-#-# [005] 47 otherfactors 47 risks associatedwith 47 Thalomid R 47 § #-#-#.# 47 incurrence 47 #.#-# [005] 47 InnSuites Hotels 47 VIOXX Lawsuits 47 USC § #u 47 § #.# [004] 46 b Represents 46 Black Canyon mica 46 orotherwise 46 #.# 5T 46 activate telomerase 46 NJAC #:#-#.# 46 multiple lease terminations 46 nancial 46 i# implanters 46 CFR § #.# [002] 46 See USSG § #D#.# 46 Subparagraph 46 See USSG § #A#.# 46 materially adversely affect 46 #.# subdivision [004] 46 obtaining regulatory approvals 46 ourproducts 46 OCGA § #-#-# [007] 46 h 46 § #.# [002] 46 contingent guaranties 46 f h 45 OCGA § #-#-#.# 45 constitute discloseable transaction 45 adversely affecting Cubist 45 APTIMA HPV assay 45 #.#-# [006] 45 Company 45 adversely affect 45 thereto 45 c Represents 45 TRISENOX R 45 xxxiii 45 USC § #a [002] 45 xiv unanticipated 45 § #.#-# [002] 45 Ferlay J et al 45 statementsregarding 45 Proposed Arrangement 45 Nasdaq Listing Rule 45 subsections b 45 regardingthe 45 substantial indebtedness 45 adverse 45 work stoppages slowdowns 45 DR #.#.# 45 #.# subd [004] 45 Slightly offsetting 45 assorted pigments resins 45 Lenfest ii 45 Second Supplemental Indenture 45 limitedto 45 Crisa acquisition 45 pharmacotherapeutics 45 CFR § #.# [005] 45 § #a [002] 45 VIOXX Product 45 Companys 45 i# implanter 45 refinance indebtedness 45 Mago ® 45 b Excludes 45 Heska reliance 45 USC § #c 45 h g 45 Put Warrant 45 Merger Transactions 45 affirmative covenants 45 g h 45 ability tosuccessfully 44 Varvarinskoye Project 44 c Relates 44 CompanyaEUR TM s 44 NYCRR #.# [001] 44 Daytrana TM 44 CFR #.# [008] 44 Repl. 44 COPL 44 Lasertel subsidiary 44 Liability Lawsuits 44 Unitholder liability 44 § #c 44 CORLUX CORT # 44 TRISENOX ® 44 CFR § #.# [001] 44 Refinancing Transactions 44 unanticipated 44 deploy MDCE services 44 CFR #.# [005] 44 Ascendiant 44 MR Civ 44 u pon 44 OCGA § #-#-# [006] 44 IRCP 44 uncollectability 44 Antler Creek Shares 44 NJSA #:#-# [004] 44 Auxilium anticipates 44 thepotential 44 consummating acquisitions 44 visit http:/www.nationwide.com 44 ti es 44 § #-#.# [003] 44 subparagraph B 44 suchforward looking 44 subjectto 44 reasonably determinable 44 PLAVIX R patent 44 § #-#-# [002] 44 #Me 44 Iusacell Celular 44 eg 44 LOVE YOU ALL 44 Proposed Transactions 44 b Reflects 44 § #b [001] 44 h r 44 § #-#-# [004] 44 i g 44 Subject 44 associatedwith 44 Bankruptcy Code § 44 Scheduler Plus 44 ARLP Partnership 44 EPIXTAR 'S 44 Direct Indirect x 44 Efficiency ratio c 44 vi renegotiation nullification 44 intercompany indebtedness 44 Bioaccelerate compounds under 44 CrR 44 -analyst Suki Cooper 44 Excess Cash Flow 44 HEI Quarterly Report 44 tenant bankruptcies 44 Wikifamilies 44 emailing dg.prospectus requests @ baml.com 44 NYCRR #.# d 44 paul dev da 44 requisite stockholder 44 tendering holders 44 Absentee Telephone 44 sequencing gene expression 44 Gastroesophageal Reflux 44 RC #.# B [001] 44 SEK -#.# -#.# [002] 44 cash fl ows 43 resultof 43 SEBI ICDR Regulations 43 SEC Rule #g# 43 date xvii Conversion 43 § #A.# 43 expenses associated therewith 43 n h r 43 Shigamabs 43 unanticipated difficulties 43 transactions contemplated 43 CFR #.# c 43 acquisitions dispositions 43 USC § #a b 43 Merged Entity 43 Somaxon ability 43 Somatuline R Autogel R 43 successfully commercialize Silenor 43 indemnification obligations 43 retrocessional coverage 43 Proposed Financing 43 c Excludes 43 IRC § 43 ofsuch 43 Direct xi Indirect 43 Earnout 43 work stoppages quarantines 43 themanagement 43 USC § #k 43 OCGA § #-#-# [005] 43 mergers consolidations 43 Direct Indirect 43 LOPROX R 43 relating thereto 43 applies prospectively 43 TriPath Oncology 43 CAUTION ANY ATTEMPT 43 g Represents 43 El Boleo Project 43 xxxi 43 w # yQ 43 Senior Subordinated Noteholders 43 ceded reinsurance 43 NxStage anticipates 43 pricing pressures 43 Partially offset 43 filingswith 43 vQsQn 43 c html plugins 43 liquidating distributions 43 #.#A [005] 43 TFC receivables 43 ie 43 FAR Clause #.#-# 43 IoGen 43 meaning ascribed thereto 43 -hooker Marius Tincu 43 § #-#-# [006] 43 -DEAD BODY 43 n h 43 gathering compressing treating 43 OREO valuation 43 Exelbine 43 #.#-# Evaluation Commercial 43 includingstatements regarding 43 NASDAQ Listing Rule 43 HealthGate ability 43 Secured Debentures 43 vii IBC 43 mhw ` 43 SOLODYN R 43 - Adjusted [003] 43 Quebecor Debtors 43 dilutive issuances 43 legal proceedings xxi 43 EGRIFTA TM 43 collaborations Pharmacopeia 43 Inside INdiana Host 43 #.# subd [006] 43 Lordsburg Mining District 43 bone marrow fibrosis 43 CFR § #.# [003] 43 Fed.R.Civ.P. 43 xxxv 43 technological innovations adversely affecting 43 Subordinated Debenture 43 xxix 43 c Includes 43 pursuant 43 Bo Scaife TE 43 unitholder liability 42 supplemental indenture containing 42 c 42 Metabasis stockholders 42 y u 42 arebased 42 SIFT Rules 42 majeure 42 § 7B 42 nonoccurrence 42 § 7A 42 accounting pronouncements 42 Julius Peppers DE 42 primarily attributable 42 successfully commercialize Iluvien 42 Registrant 42 Geomark 42 @ y qW 42 - -Billeaudeau 42 consiste 42 Expenses incurred 42 FAR #.# 42 Pa.RAP 42 - Adjusted [028] 42 REIT Exemption 42 § #-#.# [001] 42 postretirement benefit 42 PD2i Analyzer ™ 42 Represents 42 MorAmerica Capital 42 EEFC accounts 42 delinquencies defaults 42 hereof shall 42 w illus 42 Sensipar ® 42 t h eir 42 Convertible Notes tendered 42 b Includes 42 j Represents 42 LOUIS Oshiomogho Atogwe 42 -Ewurun 42 fluctuations 42 l h 42 rapid technological 42 -fulvic acids 42 Indentures governing 42 earnout provision 42 Somatuline R Depot 42 Johnell O 42 Pursuant 42 r n 42 distribu 42 attaching thereto 42 USSG § #L#.# b 42 USC § #b [001] 42 SEK -#.# [003] 42 # wQ 42 Flagstone Suisse 42 Financing Condition 42 #a subdivision 42 OraTest R 42 SEK -#.# -#.# [003] 42 obligations thereunder 42 Lordsburg mill comprising 42 - - Non GAAPHawai'i Paroling Authority 42 CrR #.# 42 intangible asset impairments 42 Informal Agreements 42 -PROCTOR Water 42 Receivable purchasing 42 therefrom 42 Senior Secured Debentures 42 SonoPrep device 42 affecting Amarin 42 affecting mortality morbidity 42 product introductions 42 novel therapeutic modality 42 QM Technologies 42 financialstatements 42 torsemide ER 42 ecotoxicity 42 commercialize ZYFLO CR 42 involverisks 42 b Vernon Supp 42 Consists primarily 42 SIFT Tax 42 Purchased Assets 42 consents authorizations 42 BiDil XR drug 42 connection therewith 42 non capitalizable 42 DRAXIS 42 NJSA #:#-#.# [003] 42 Partially offsetting 42 wv ` 42 permitting timelines 42 BreitBurn GP LLC 42 Zanaflex Capsules 42 l l 42 benefi t 42 promissory notes payable 42 #.#-# Offeror Representations 42 Bidding Procedures 42 principally attributable 42 Mircette R 42 risks anduncertainties 42 #.#-# Instructions 42 Xechem Nigeria 42 askus@georgeson.com 42 Reports Inducement Grants 42 u h 42 earnout payment 42 manufacture PolyHeme 42 USC § #a [001] 42 Bonterra Trust 42 contingently liable 42 Annexures 42 Enlarged Group 42 Oligator R oligonucleotides iv 42 Private Placement Offering 42 Minimum Tender Condition 42 No. #R Consolidation 42 § #.# [001] 41 LAE reserves 41 AvenEx 41 Contingent Value Rights 41 Prof. Code § 41 product discontinuances 41 Analyte Specific Reagent 41 offuture 41 OCGA § #-#-# [004] 41 OCGA § #-#-# [003] 41 Urocidin TM 41 -#,# -#,# -#,# -#,# [003] 41 compliance therewith 41 i 41 Subordinate Voting Stock 41 Beneficial Ownership 41 ii ultrasonic 41 EMPOWER pivotal trial 41 Insolvency Proceedings 41 #g# 2 41 depreciation depletion amortization 41 - Non GAAP [009] 41 #,#,# Commitments 41 § #.# subd [005] 41 Amended Credit 41 § #E 41 PD2i Analyzer 41 CDO financings 41 without limitation Terremark 41 EXPENSES Employee Compensation 41 Allovectin 7 r 41 NASDAQ Deficiency Notice 41 Aumento 41 notlimited 41 market PolyHeme commercially 41 haemophilus influenzae type 41 Medigen 41 Market Disruption 41 CFR #.# [007] 41 CoStar stent 41 ocial 41 roducts 41 SeraCare competitors 41 Rule #:#-# [001] 41 uncollectible accounts receivable 41 suchstatements 41 RESTASIS ® 41 ALS Analytical 41 SANCTURA SANCTURA XR VANTAS 41 USC § #a c 41 theavailability 41 TranSwitch indebtedness 41 risks associated therewith 41 -Dehring Bunting 41 specifi ed 41 Assurance Pensions 41 Biomerge 41 MTRCL 41 without limitation EMRISE 41 JUVISTA 41 SECURITIES ACT RSO 41 Puricase PEG uricase 41 Standby Purchasers 41 contingent liabilities 41 party VLSI fabrication 41 promissory note receivable 41 § #.# [003] 41 refl ect 41 § #.#-# [006] 41 Nortek Holdings 41 CFR #.# [006] 41 First Instalment 41 Questcor intellectual property 41 Required Consents 41 causeactual results 41 Services LLC SPIAS 41 DIP Facility 41 Scrip Dividend Scheme 41 productsand services 41 VIACOM INC. AND SUBSIDIARIES 41 Embedded Derivatives 41 NEG Holding 41 Complete Liquidation 41 HF Lenfest member 41 HRS § #-# [001] 41 NEGI 41 covenant defaults 41 Photowatt France 41 debt extinguishments 41 Sepracor anticipates 41 § #.# [006] 41 Vernon Supp 41 materially adversely affected 41 PolyNovo 41 adversely impact 41 Publication Classified Ad 41 Excludes 41 andoperating 41 andrelated 41 Liquor Stores LP 41 ofany 41 Innovision Shares 41 ultimate recoverability 41 Share Consideration 41 Variable Interest Entities FIN 41 hong kong > 41 fcmi buying 41 ProLogis Declares Dividends 41 e mail lifestyle@readingeagle.com 41 utilize FFO NOI 41 -lipid nanoparticles 41 Excludes amortization 41 Refining Segment 41 CFR § § #.# [002] 41 persistent muscle spasms 41 subordinated promissory notes 41 Enpath ability 41 doubtful accounts receivable 41 Gamecorp 41 adopting SFAS #R 41 Restated Revolving Credit 41 GYN Surgical revenues 41 Premium DRIP 41 passenger Silver Whisper 41 Excluding acquisitions divestitures 41 OSI Pharmaceuticals filings 41 Compans 41 respect thereto 41 andmarket 41 - Adjusted [006] 41 vii Dynamic 41 Pa. Code § 41 Idenix anticipates 41 arising therefrom 41 Maimon Mine 41 anduncertainties 41 cturing 41 en tant 41 xi unanticipated 41 consequent 41 Triage BNP Test 41 Plenaxis R 41 Pa.CSA § 41 OFCD Optionally Fully 41 L imited 41 Agreement constitutes discloseable 41 ENABLE Phase 2 41 sublease recoveries 41 BioGlue ® 41 outstanding indebtedness 41 Nascobal R 41 FOB Destination 41 ERISA § 41 requisite regulatory approvals 41 Wider Trintech Group 40 ADA CS 40 cancellations rescheduling 40 irrevocably authorizes 40 Purchased intangibles 40 § #.#.# [002] 40 PLAVIX ® 40 FastFunds Financial Corporation 40 NitroMed BiDil 40 Petrowest 40 DELATESTRYL 40 Preferential Allotment 40 substantiate CytoCore expectations 40 CFR § § #.# [001] 40 u t 40 Senior Secured Convertible 40 USC § #a [003] 40 Concurrent Financing 40 BCGI Shareholders 40 alemtuzumab MS 40 OTC ZEGERID 40 Noncash investing 40 La.Code Crim.P. art 40 Tsavo Acquisition 40 Exelixis compounds 40 Bioenvision dependence 40 y r 40 obsolete inventory 40 Reinsurance recoverables 40 BioGlue R 40 Subsection c 40 earnout payments 40 incidental thereto 40 Certifications Commercial 40 celgosivir 40 render PolyHeme obsolete 40 NRS #.# [003] 40 UBS SFIs 40 RC #.# B [002] 40 Somewhat offsetting 40 = Weighted average [026] 40 MicroTel 40 ac ti 40 cmt 40 Healive TM 40 Oxandrin R 40 Financing Agreements 40 n mn mn 40 PROCHIEVE ® 40 Supp. 40 subds 40 pany 40 Prelude SkinPrep Systems 40 uncertaintiesthat 40 aux côtés 40 Irinotecan Hydrochloride Injection 40 LSA RS #:# [001] 40 Interest Drawdown Date 40 areforward looking 40 paul gordon 40 ADSI reliance 40 NCGS § #A 40 incorporate proprietary Microvolt 40 heading RISK FACTORS 40 periodic redeterminations 40 - Non GAAP [008] 40 INACCURACIES 40 r t 40 FACTIVE tablets 40 requisite Consents 40 vii Cubist ability 40 Panostaja Oyj Panostaja oyj 40 requirements xxii 40 aux actionnaires 40 HemoStase 40 Rules #b# 40 Nexaira BCII router 40 intercompany loans 40 Transeastern JV 40 Visa indemnification 40 telavancin NDA 40 Discovery Labs 40 Oxandrin ® 40 Canexus LP 40 LPM TM 40 ADVENTRX 40 Value Creation Plan 40 inaccuracy therein 40 futureresults 40 CDFS joint ventures 40 Prochieve R 40 MethyPatch 40 amortizable intangible assets 40 NOL utilization 40 NYCRR #.# [003] 40 Stockholder Approval 40 Charlie Manuel flips 40 au cours des 40 ffect 40 Sponsored REITs 40 postretirement 40 - Adjusted [017] 40 OR FOR DISCRETIONARY 40 Contingent Consideration 40 UILIC 40 [036] 40 INVESTMENT PLAN 40 Subsection b 40 GASFRAC 40 Oxandrin 40 Kunekt 40 Theragenics Corporation 40 historicalfacts 40 Accrual 40 Civil Procedure Rule 40 postretirement benefit obligations 40 risksand uncertainties 40 Installment Payment 40 retrocessions 40 mw http :/ finance.yahoo.com 40 Generx TM 40 cytochrome c oxidase 40 § #-#-# [007] 40 § #.#.# [001] 40 EVIZON TM squalamine lactate 40 Membership Interests 40 differ materiallyfrom 40 successfully commercialize 40 -#,# -#,# [002] 40 DFAR #.#-# 40 Yima project 40 commercialize BiDil 40 ™ pralatrexate injection 40 thereby negatively impacting 40 FINRA Rule 40 ` rk 40 OTC ZVTK 40 Derivative instruments 40 -Inc. Amex IAO 40 Ordinary Unitholders 40 Indirect Costs 40 AdhTAP 40 Marketplace Rules 40 ofnew 40 = strlen 40 Multiplied Media announces 40 intercompany transactions 40 retrocessional reinsurance 40 t h r 40 otherrisks 40 Initial Purchasers 40 className nodes nodes.length = 40 microg 40 CICA Accounting Guideline 40 DELETE OR EDIT COMMENTS 40 Fourth Supplemental Indenture 40 Maintenance Requirements 40 SumTotal Enterprise 40 * ls 40 incorporate CXA 40 Xantic acquisition 40 ISIN Number 40 #-#.# [016] 40 TP# CETi 1 40 Sodisco Howden 40 Vyvx advertising 40 HDF therapy 40 Non Dilutive 40 Bexil Advisers 40 Solicitation Statement 40 oversubscription privilege 40 KRYSTEXXA TM 40 § #-# [004] 40 Pr Ser 40 TrueKnowledge Platform TM 40 applicable regulatory approvals 40 h u 40 en vertu de la 40 Androxal TM 40 Duska intends 40 LOI contemplates 40 WpHG mit dem Ziel 40 Solectron stockholders 40 Bluebeam Conversion Server 40 minesites 40 #A.# [005] 40 CFR #.# d 40 MRL Offers 40 c Reflects 40 CIP FENOFIBRATE 40 market fluctuations investee 40 DDJET partnership 40 itsbusiness 40 Immunotherapeutic 40 TransVax tm 40 Regulation Section #.#-# 40 Tecstar Automotive Group 40 uts 40 SEC Rule #b 40 Reg. S 40 SILO LILO charges 40 generic clopidogrel bisulfate 40 CFR #.# b 40 omecamtiv mecarbil 40 Bond Indenture 40 unconsolidated investees 40 AspenTech periodic reports 40 Underlying Share 40 novel emulsion formulation 40 franking credits attached 40 consummation 40 cadence regulatory approvals 40 Defendants misrepresented 40 USED IN FINANCING ACTIVITIES 40 Entrust Quarterly Report 40 AzaSite Plus 40 - Non Shane Germann 40 Hiru Corp. 40 validly consented 40 Hexion Proposal 40 Company noncontributory defined 40 dispositions joint ventures 40 candidate Ramoplanin 40 Maxipime 40 STRIANT R 40 LTCHs 40 KRS #.# [003] 40 realizable value 40 TRISENOX 40 émises 40 -Civilian Nuclear 40 Alnylam dependence 40 Specified Investment 40 END FOOTNOTE FOOTNOTE 40 applicable Offering Memorandum 40 Dangaard Holding 40 AERx ® 40 Inaddition 40 Superior Achiever 40 SG &A; 40 #IA 40 g 40 § #:# [001] 40 en actions ordinaires 40 Non recurring 40 #.# subds [001] 40 Sponsor sole discretion 40 readily determinable 40 event reporting Clintrace 40 Dobhai 40 - Non GAAP [002] 40 Evid. Code § § 40 fprintf stderr 40 Variable Interest Entities VIEs 40 Escrow Release 40 - Adjusted [024] 40 SOLTAMOX 40 krn 40 risks associated 40 Tianshi Engineering 40 % Inpatient catheterization 40 consiste en 40 Deborah Battiston 40 Omtool periodic reports 40 Note Receivable 40 #,#,# #,#,# -DH Ellis Burks 40 CPLR § 40 heading ITEM 1A 40 manganese ii 40 mergers dispositions 40 Accounting Standard AASB 40 f Reflects 40 -Maddur 40 Section #-#-# [006] 40 #.# subds [002] 40 Canbras 40 flwyddyn 40 patented BEMA TM 40 Accurel 40 proceeds therefrom 40 stock basedcompensation 40 SB# Provides 40 Fampridine SR Acorda Therapeutics 40 Priority Unitholders 40 entities VIE 40 #,#,# #,#,# -shameful betrayal 40 documentation evidencing 40 fi xed 40 adversely affect Waste Connections 40 -Tilak Marg 40 pegylated IFN 40 subsidiaries Kindred Brookdale 40 InsCom 40 #A.# [001] 40 postemployment 40 Filtran Microcircuits Inc. 39 affecting BEO Bancorp 39 Deconsolidation 39 rights xix xx 39 VimpelCom disclaims 39 .W. McNichols 39 USCS § 39 USSG § #B#.# [002] 39 potentially mineable widths 39 VeraTag assays 39 MOSAID litigation 39 -Amos Harel Haaretz Correspondent 39 PharmaBio 39 DMEPOS supplier 39 #,# -Marhoefer 39 persistency mortality 39 - Adjusted [016] 39 Tenn. R. Civ 39 Variable Interest Rate 39 PRAVACHOL R 39 wQ @ b 39 @ gn 39 Cash Consideration 39 Elevess 39 ARIF II 39 postpetition 39 Applicable Margin 39 Partnered Brands segment 39 Date xiv 39 INTEGRILIN ® 39 ProBiora3 ® 39 Code § #A [002] 39 accruals 39 excluding BIBP 39 i. 39 Stockholder Voting 39 Stena Compassion 39 DTR#.#.# b 39 FierceGovernmentIT tracks 39 LIFO adjustments 39 Wolf Haldenstein Investigates 39 difficulties foreseeing 39 TXU DevCo 39 ecting 39 CEFF financings subject 39 Ultane Sevorane 39 DTR#.#.# 39 materially overstating 39 CCH Pension Plan 39 ad valorem taxing 39 PD2i Cardiac Analyzer 39 NPREIT 39 y h 39 NCGS § 7B 39 expropriation nationalization 39 Gov't Code § 39 butable 39 dimesylate Attention Deficit 39 Publicly Held Shares 39 l o 39 DISMISSED WITH PREJUDICE 39 XP# XP#